Alyra focuses on discovering compounds that inhibit protein-protein interactions (PPIs), which are involved in the development of diseases such as cancer, autoimmune disease, and neurodegenerative disorders. Their lead program, ALY101, blocks the interactions of proteins that contribute to tumor growth and blood vessel formation across various tumor types. By inhibiting the activity of a protein called PAK1, ALY101 shows potential as a treatment for multiple cancers and rare diseases like Ewing sarcoma and neurofibromatosis type 2. Alyra is collaborating with academic institutions like Indiana University and Baylor College of Medicine to explore the potential of ALY101 in treating these diseases.